[Use and effectiveness of norethisterone enanthate for family planning in a rural area]. / Uso y efectividad del enantato de noretisterona para la planificación familiar en el área rural.
Ginecol Obstet Mex
; 51(314): 163-7, 1983 Jun.
Article
em Es
| MEDLINE
| ID: mdl-6681299
PIP: The objective of this study was to analyze the acceptability, effectiveness, and continuation of long-acting progestagens in certain sectors of the population where its advantages are more obvious by virtue of certain socioeconomic, cultural, and geographic characteristics, and by lack of availability of family planning services, as in rural areas and urban marginal zones. The study was performed using females of reproductive age residing in rural areas of the Mexican States of Hidalgo, Puebla, and Yucatan between July 1981 and September 1982. Originally the investigation included a total of 462 women, of whom 94 were lost to follow-up, leaving a total of 368 patients (79.6%) with effective follow-up. The contraceptive used was 19-Nor progestagen, norethisterone enanthate (NET), in 200 mg doses administered intramuscularly. The 1st dose was applied between the 1st to the 5th day of the menstrual cycle and each 60 calendar days thereafter. Of a total of 94 discontinuations, 2/3 occurred during the 1st 6 months of the study. The final discontinuation rate was 14.46%. The studied population showed a continuation rate of 85.54% after 12 months of use. Observing rates by reasons for discontinuation, the principal causes in descending order were nonmedical reasons, amenorrhea, pregnancy, bleeding and other secondary effects. The greatest number of discontinuations, considering each particular reason, occurred predominantly during the 1st 6 months of the study. Distribution of users by age group show that more than 2/3 (71.8%) were between 20 and 34 years old. Distribution by number of previous pregnancies show 56.5% with 5 or more gestations. To analyze behavior of menstrual cycles, "cycles" were defined as period of 30 calendar days. Under this concept, more than 2/3 (70.9%) of the users had from 1 to 7 days of bleeding per cycle. On the basis of the results of the study, it is possible to conclude the following: 1) Continuation of NET use is greater than that observed with other long-lasting progestagens. This seems to be especially so when employed in areas where limitations exist for the utilization of other contraceptive means. 2) Contraceptive effectiveness is greater when administration is scheduled at 60 day intervals rather than longer intervals. 3) Unlike other long-acting progestagens, NET conserves the normal menstrual pattern in the majority of users, which favorably influences its continuation.^ieng
Palavras-chave
Acceptor Characteristics; Acceptors; Amenorrhea; Americas; Biology; Central America; Contraception Continuation; Contraception--side effects; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Methods--side effects; Contraceptive Usage; Developed Countries; Developing Countries; Diseases; Endocrine System; Evaluation; Family Planning; Family Planning Program Evaluation; Family Planning Programs; Genital Effects, Female; Health Services Evaluation; Hormones--side effects; Injectables--side effects; Latin America; Measurement; Menstrual Cycle; Menstruation; Menstruation Disorders; Method Acceptability; Mexico; Norethindrone Enanthate--side effects; Norethindrone--side effects; North America; Organization And Administration; Physiology; Population; Population Characteristics; Program Evaluation; Programs; Qualitative Evaluation; Reproductive Control Agents--side effects; Research Methodology; Rural Population; Urogenital Effects
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Anticoncepcionais Femininos
/
Noretindrona
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Pregnancy
País/Região como assunto:
Mexico
Idioma:
Es
Revista:
Ginecol Obstet Mex
Ano de publicação:
1983
Tipo de documento:
Article
País de publicação:
México